全文获取类型
收费全文 | 4257篇 |
免费 | 227篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 279篇 |
妇产科学 | 165篇 |
基础医学 | 446篇 |
口腔科学 | 90篇 |
临床医学 | 370篇 |
内科学 | 798篇 |
皮肤病学 | 42篇 |
神经病学 | 209篇 |
特种医学 | 669篇 |
外科学 | 652篇 |
综合类 | 49篇 |
预防医学 | 161篇 |
眼科学 | 104篇 |
药学 | 239篇 |
中国医学 | 7篇 |
肿瘤学 | 216篇 |
出版年
2021年 | 38篇 |
2020年 | 36篇 |
2019年 | 31篇 |
2018年 | 53篇 |
2017年 | 39篇 |
2016年 | 67篇 |
2015年 | 76篇 |
2014年 | 94篇 |
2013年 | 123篇 |
2012年 | 146篇 |
2011年 | 134篇 |
2010年 | 148篇 |
2009年 | 118篇 |
2008年 | 141篇 |
2007年 | 142篇 |
2006年 | 119篇 |
2005年 | 129篇 |
2004年 | 138篇 |
2003年 | 117篇 |
2002年 | 120篇 |
2001年 | 110篇 |
2000年 | 124篇 |
1999年 | 91篇 |
1998年 | 158篇 |
1997年 | 145篇 |
1996年 | 142篇 |
1995年 | 117篇 |
1994年 | 96篇 |
1993年 | 106篇 |
1992年 | 76篇 |
1991年 | 54篇 |
1990年 | 54篇 |
1989年 | 109篇 |
1988年 | 75篇 |
1987年 | 91篇 |
1986年 | 81篇 |
1985年 | 88篇 |
1984年 | 53篇 |
1983年 | 48篇 |
1982年 | 54篇 |
1981年 | 36篇 |
1980年 | 59篇 |
1979年 | 46篇 |
1978年 | 46篇 |
1977年 | 44篇 |
1976年 | 46篇 |
1975年 | 62篇 |
1973年 | 39篇 |
1970年 | 32篇 |
1969年 | 29篇 |
排序方式: 共有4516条查询结果,搜索用时 15 毫秒
1.
George Haddad Malte Klling Urs A. Wegmann Angela Dettling Harald Seeger Roland Schmitt Inga Soerensen-Zender Hermann Haller Andreas D. Kistler Anne Dueck Stefan Engelhardt Thomas Thum Thomas F. Mueller Rudolf P. Wüthrich Johan M. Lorenzen 《Journal of the American Society of Nephrology : JASN》2021,32(2):323
2.
Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma
3.
4.
5.
Song Xue Amanda Posgai Clive Wasserfall Courtney Myhr Martha Campbell-Thompson Clayton E. Mathews Todd Brusko Alex Rabinovitch Alexei Savinov Manuela Battaglia Desmond Schatz Michael Haller Mark A. Atkinson 《Diabetes》2015,64(11):3873-3884
An increasing number of therapies have proven effective at reversing hyperglycemia in the nonobese diabetic (NOD) mouse model of type 1 diabetes (T1D), yet situations of successful translation to human T1D are limited. This may be partly due to evaluating the effect of treating immediately at diagnosis in mice, which may not be reflective of the advanced disease state in humans at disease onset. In this study, we treated NOD mice with new-onset as well as established disease using various combinations of four drugs: antithymocyte globulin (ATG), granulocyte-colony stimulating factor (G-CSF), a dipeptidyl peptidase IV inhibitor (DPP-4i), and a proton pump inhibitor (PPI). Therapy with all four drugs induced remission in 83% of new-onset mice and, remarkably, in 50% of NOD mice with established disease. Also noteworthy, disease remission occurred irrespective of initial blood glucose values and mechanistically was characterized by enhanced immunoregulation involving alterations in CD4+ T cells, CD8+ T cells, and natural killer cells. This combination therapy also allowed for effective treatment at reduced drug doses (compared with effective monotherapy), thereby minimizing potential adverse effects while retaining efficacy. This combination of approved drugs demonstrates a novel ability to reverse T1D, thereby warranting translational consideration. 相似文献
6.
Josh W. Pressler April Haller Joyce Sorrell Fei Wang Randy J. Seeley Patrick Tso Darleen A. Sandoval 《Diabetes》2015,64(2):498-507
Bariatric surgery is the most successful strategy for treating obesity, yet the mechanisms for this success are not clearly understood. Clinical literature suggests that plasma levels of apolipoprotein A-IV (apoA-IV) rise with Roux-en-Y gastric bypass (RYGB). apoA-IV is secreted from the intestine postprandially and has demonstrated benefits for both glucose and lipid homeostasis. Because of the parallels in the metabolic improvements seen with surgery and the rise in apoA-IV levels, we hypothesized that apoA-IV was necessary for obtaining the metabolic benefits of bariatric surgery. To test this hypothesis, we performed vertical sleeve gastrectomy (VSG), a surgery with clinical efficacy very similar to that for RYGB, in whole-body apoA-IV knockout (KO) mice. We found that VSG reduced body mass and improved both glucose and lipid homeostasis similarly in wild-type mice compared with apoA-IV KO mice. In fact, VSG normalized the impairment in glucose tolerance and caused a significantly greater improvement in hepatic triglyceride storage in the apoA-IV KO mice. Last, independent of surgery, apoA-IV KO mice had a significantly reduced preference for a high-fat diet. Altogether, these data suggest that apoA-IV is not necessary for the metabolic improvements shown with VSG, but also suggest an interesting role for apoA-IV in regulating macronutrient preference and hepatic triglyceride levels. Future studies are necessary to determine whether this is the case for RYGB as well. 相似文献
7.
EH Gemmill DJ Humes JA Catton 《Annals of the Royal College of Surgeons of England》2015,97(3):173-179
Introduction
Fast track methodology or enhanced recovery schemes have gained increasing popularity in perioperative care. While evidence is strong for colorectal surgery, its importance in gastric and oesophageal surgery has yet to be established. This article reviews the evidence of enhanced recovery schemes on outcome for this type of surgery.Methods
A systematic literature search was conducted up to March 2014. Studies were retrieved and analysed using predetermined criteria.Results
From 34 articles reviewed, 18 eligible studies were identified: 7 on gastric and 11 on oesophageal resection. Three randomised controlled trials, five case-controlled studies and ten case series were identified. The reported protocols included changes to each stage of the patient journey from pre to postoperative care. The specific focus following oesophageal resections was on early mobilisation, a reduction in intensive care unit stay, early drain removal and early (or no) contrast swallow studies. Following gastric resections, the emphasis was on reducing epidural anaesthesia along with re-establishing oral intake in the first three postoperative days and early removal of nasogastric tubes.In the papers reviewed, mortality rates following fast track surgery were 0.8% (9/1,075) for oesophageal resection and 0% (0/329) for gastric resection. The reported morbidity rate was 16.5% (54/329) following gastric resection and 38.6% (396/1,075) following oesophageal resection. Length of stay was reduced in both groups compared with conventional recovery groups in comparative studies.Conclusions
The evidence for enhanced recovery schemes following gastric and oesophageal resection is weak, with only three (low volume) published randomised controlled trials. However, the enhanced recovery approach appears safe and may be associated with a reduction in length of stay. 相似文献8.
Caroline Schultheiß René Weischenberg Andrea Herrmann Bernhard Haller Roland M. Schmid Wolfgang Reindl Wolfgang Huber 《Artificial organs》2015,39(2):187-192
Granulocyte‐monocyte apheresis (GMA) is an emerging therapeutic option in active course of ulcerative colitis (UC). Appropriate GMA dose, including total number, frequency, and duration of the individual GMA session, is a matter of debate. It was the aim of the present study to evaluate the efficacy of a dose‐intensified GMA regimen in patients with moderately to severely active UC. A prospective open‐label, single‐center study was performed in 10 patients with active UC (Rachmilewitz Clinical Activity Index [CAI] ≥ 8 points; Rachmilewitz Endoscopic Index ≥ 7 points). Patients had failed to improve after treatment with steroids and/or immunomodulators. GMA was performed twice weekly for 2 h to a maximum of 10 sessions. In each GMA session, the adsorber was changed after 1 h of treatment time. Four patients achieved remission with a CAI ≤ 4 points. Three patients had a response with an improvement of CAI of ≥3 points. Three patients showed no benefit from GMA. The quality of life score determined by the inflammatory bowel disease questionnaire‐Deutschland increased by 26 points in median. First and second filters had similar efficiency in granulocyte and monocyte adsorption. No major adverse effects were observed. Dose‐intensified GMA as reported in this study provided an encouraging short‐term response rate of 70% in patients with moderately to severely active UC not responding to standard steroid or immunomodulator therapy. Although all patients relapsed not later than 16 weeks, GMA might be useful to reduce steroid and immunomodulator usage, or to delay surgery in this patient group. 相似文献
9.
10.
Nemandra Sandiford SK Muirhead-Allwood JA Skinner 《Indian Journal of Orthopaedics》2015,49(6):595-601